Skip to main content

Advertisement

Table 4 Comparison of patients with versus without sustained function

From: Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters

  Patients with SF at fifth year, n = 84 Patients without SF at fifth year, n = 23 p Valuea
Sociodemographic variables    
 Female sex, number (%) of patients 73 (86.9) 22 (95.7) 0.46
 Age at baseline, yr (mean ± SD) 36.1 ± 12.2 48.5 ± 13.6 0.000
 Years of formal education (mean ± SD) 11.3 ± 3.9 9.7 ± 4.2 0.09
 Current smokers, number (%) of patients 9 (10.7) 0 (0) 0.2
Disease characteristics at baselineb    
 Disease duration, mo 5.3 (3.8–7.5) 3.8 (2.5–6.2) 0.05
 Patients with RF, n (%) 69 (82.1) 19 (82.6) 1
 Patients with ACCP, n (%) 72 (85.7) 20 (87) 1
 DAS28 6 (4.9–6.9) 6.8 (6–7.7) 0.02
 HAQ 1.4 (0.8–2) 2.1 (1.6–3) 0.000
 Patients with erosions, n (%) 9 (10.7) 2 (8.7) 1
Number (%) of patients with ≥1 comorbidity 65 (77.4) 20 (87) 0.39
Number of comorbidities/patient 1 (1–2) 2 (1–2.8) 0.2
Cumulative treatment characteristicsb    
 Patients with corticosteroids, n (%) 42 (50) 16 (69.6) 0.11
 Number of DMARDs/patient 2.3 (1.9-2.9) 2.4 (2–3) 0.44
 Number (%) of patients with ≥1 non-persistence period 57 (76.9) 17 (73.9) 0.8
 Follow-up at first non-persistence period,c mo 13 (1–31) 13 (1–22) 0.25
 Persistence duration, mod 42 (30–48) 36 (12–48) 0.08
  1. ACCP anti-cyclic citrullinated peptide antibodies, DAS28 Disease Activity Score in 28 joints, DMARDs disease-modifying anti-rheumatic drugs, HAQ Health Assessment Questionnaire, RF rheumatoid factor, SD standard deviation, SF sustained function
  2. a p < 0.05 is statistically significant
  3. bData presented as median (25th–75th interquartile range) unless otherwise indicated
  4. cRestricted to 74 patients with ≥1 non-persistence period
  5. dIn the whole population